Globus Medical (NYSE:GMED) issued an update on its FY 2020
After-Hours earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.82-1.82 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.92. The company issued revenue guidance of $850-850 million, compared to the consensus revenue estimate of $854.39 million.Globus Medical also updated its FY 2019
After-Hours guidance to EPS.
Shares of NYSE GMED traded up $0.10 during midday trading on Thursday, hitting $52.96. 117,414 shares of the company traded hands, compared to its average volume of 472,052. Globus Medical has a 12-month low of $38.37 and a 12-month high of $60.15. The stock has a 50-day moving average price of $57.31 and a 200 day moving average price of $51.28. The firm has a market cap of $5.27 billion, a P/E ratio of 31.71, a P/E/G ratio of 2.70 and a beta of 0.96.
Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.01. The company had revenue of $196.22 million for the quarter, compared to analysts’ expectations of $185.86 million. Globus Medical had a net margin of 19.03% and a return on equity of 13.09%. Globus Medical’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.39 earnings per share. Sell-side analysts predict that Globus Medical will post 1.71 earnings per share for the current year.
In other Globus Medical news, SVP Kelly Huller sold 6,460 shares of Globus Medical stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $58.90, for a total value of $380,494.00. Following the completion of the transaction, the senior vice president now directly owns 3,076 shares of the company’s stock, valued at approximately $181,176.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David D. Davidar sold 38,000 shares of Globus Medical stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $54.00, for a total transaction of $2,052,000.00. Following the completion of the transaction, the director now directly owns 666,775 shares of the company’s stock, valued at $36,005,850. The disclosure for this sale can be found here. Insiders have sold 50,460 shares of company stock valued at $2,758,894 over the last ninety days. 24.97% of the stock is currently owned by corporate insiders.
Globus Medical Company Profile
Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches.
Further Reading: Hedge Funds Explained
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.